170 related articles for article (PubMed ID: 15028303)
1. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS.
Roka S; Rudas M; Taucher S; Dubsky P; Bachleitner-Hofmann T; Kandioler D; Gnant M; Jakesz R
Eur J Surg Oncol; 2004 Apr; 30(3):243-7. PubMed ID: 15028303
[TBL] [Abstract][Full Text] [Related]
2. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
Sakorafas GH; Tsiotou AG
Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
[TBL] [Abstract][Full Text] [Related]
5. Contemporary treatment of ductal carcinoma in situ of the breast.
Mokbel K
Med Sci Monit; 2005 Mar; 11(3):RA86-93. PubMed ID: 15735580
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
7. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience.
Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R
Breast J; 2005; 11(4):242-7. PubMed ID: 15982389
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
Mechera R; Viehl CT; Oertli D
Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
[TBL] [Abstract][Full Text] [Related]
9. Treatment of ductal carcinoma in situ of the breast: review of recent advances and future prospects.
Mokbel K
Int J Fertil Womens Med; 2003; 48(5):217-25. PubMed ID: 14626378
[TBL] [Abstract][Full Text] [Related]
10. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy and tamoxifen after breast-conserving surgery for DCIS.
Cunnick GH; Mokbel K
Int J Fertil Womens Med; 2004; 49(5):237-8. PubMed ID: 15633483
[TBL] [Abstract][Full Text] [Related]
12. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
[TBL] [Abstract][Full Text] [Related]
13. Ductal carcinoma in situ of the breast -- among factors predicting for recurrence, distance from the nipple is important.
Stallard S; Hole DA; Purushotham AD; Hiew LY; Mehanna H; Cordiner C; Dobson H; Mallon EA; George WD
Eur J Surg Oncol; 2001 Jun; 27(4):373-7. PubMed ID: 11417983
[TBL] [Abstract][Full Text] [Related]
14. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
[TBL] [Abstract][Full Text] [Related]
15. Recent advances and current controversies in the management of DCIS of the breast.
Sakorafas GH; Farley DR; Peros G
Cancer Treat Rev; 2008 Oct; 34(6):483-97. PubMed ID: 18490111
[TBL] [Abstract][Full Text] [Related]
16. Is sentinel node biopsy necessary in conservatively treated DCIS?
Julian TB; Land SR; Fourchotte V; Haile SR; Fisher ER; Mamounas EP; Costantino JP; Wolmark N
Ann Surg Oncol; 2007 Aug; 14(8):2202-8. PubMed ID: 17534687
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
18. Local recurrences after conservative treatment of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age.
Schouten van der Velden AP; Peeters PH; Koot VC; Hennipman A
Ann Surg Oncol; 2006 Jul; 13(7):990-8. PubMed ID: 16788762
[TBL] [Abstract][Full Text] [Related]
19. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast.
Hoque A; Lippman SM; Boiko IV; Atkinson EN; Sneige N; Sahin A; Weber DM; Risin S; Lagios MD; Schwarting R; Colburn WJ; Dhingra K; Follen M; Kelloff GJ; Boone CW; Hittelman WN
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):249-59. PubMed ID: 11303595
[TBL] [Abstract][Full Text] [Related]
20. Long-term cosmesis after lumpectomy and brachytherapy in the management of carcinoma of the previously irradiated breast.
Trombetta M; Julian TB; Werts DE; McWilliams W; Kim Y; Miften M; Parda D
Am J Clin Oncol; 2009 Jun; 32(3):314-8. PubMed ID: 19451803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
